博雅生物(300294) - 2025 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net profit of approximately ¥10,500 million for 2025, representing a decline of 65.62% to 73.55% compared to the previous year[4] - Revenue is projected to be between ¥190,839 million and ¥216,863 million, indicating a year-on-year increase of 10.00% to 25.00%[4] - Non-recurring gains and losses are estimated to impact net profit by approximately ¥1.2 billion, compared to ¥0.95 billion in the same period last year[6] - The financial data in the earnings forecast has not been audited by external auditors[5] - The specific financial figures will be detailed in the company's 2025 annual report[7] Acquisition Impact - The decline in net profit is primarily due to a ¥3 billion impairment loss on intangible assets and goodwill related to the acquisition of Green Cross Hong Kong Holdings Limited[6] - The acquisition of Green Cross Hong Kong Holdings Limited is expected to contribute to the revenue growth[5] Market Challenges - The blood products business has faced challenges due to increased market competition and regulatory changes, leading to a decrease in clinical prescription volumes[6] - The company is implementing a "1246" model and focusing on "four remakes" to navigate the complex market environment[5] Investor Guidance - Investors are advised to make cautious decisions and be aware of investment risks[7]